Arrowhead Pharmaceuticals (ARWR) vs Ionis Pharmaceuticals (IONS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Arrowhead Pharmaceuticals (ARWR) has outperformed Ionis Pharmaceuticals (IONS) over the past year, gaining 68.3% versus a loss of 35.9%. Over five years, IONS leads with a +25.8% price change compared with -7.1% for ARWR. Arrowhead Pharmaceuticals is the larger company by market cap ($8.55 billion vs $7.22 billion), about 1.2 times the size.
Arrowhead Pharmaceuticals converts more of its revenue into profit, with a net margin of -0.2% versus -40.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARWR | IONS |
|---|---|---|
| Share price | $60.50 | $43.46 |
| Market cap | $8.55B | $7.22B |
| 1-day change | -1.59% | -1.60% |
| YTD return | -7.40% | -44.18% |
| 1-year return | +68.25% | -35.94% |
| 5-year return | -7.07% | +25.81% |
| EPS (TTM) | $-2.28 | $-3.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $829.45M | $943.71M |
| Revenue growth (YoY) | +23258.15% | +33.83% |
| Net income (latest FY) | $-1.63M | $-381.39M |
| Gross margin | — | 98.31% |
| Operating margin | 11.86% | -40.45% |
| Net margin | -0.20% | -40.41% |
| 52-week high | $95.49 | $86.74 |
| 52-week low | $34.61 | $42.63 |
| Distance from 52-week high | -36.64% | -49.90% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +77.24% | +92.47% |
| Average volume | 1.90M | 3.78M |
| Shares outstanding | 141.25M | 166.18M |
| Employees | 711 | 1,480 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARWR has outperformed IONS by 104.2 percentage points over the past year.
- Arrowhead Pharmaceuticals is more profitable, keeping -0.2 cents of every revenue dollar as net income versus -40.4 cents for Ionis Pharmaceuticals.
- Arrowhead Pharmaceuticals grew revenue faster in its latest fiscal year (+23258.15% vs +33.83%).
About Arrowhead Pharmaceuticals
ARWR stock →Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 711 employees
About Ionis Pharmaceuticals
IONS stock →Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA).
Health Care · Biotechnology: Pharmaceutical Preparations · 1,480 employees
ARWR vs IONS FAQ
Which is bigger, Arrowhead Pharmaceuticals or Ionis Pharmaceuticals?
Arrowhead Pharmaceuticals (ARWR) is larger, with a market capitalization of $8.55B compared with $7.22B for Ionis Pharmaceuticals (IONS).
Which stock has performed better over the past year, ARWR or IONS?
ARWR returned +68.25% over the past 12 months, compared with -35.94% for IONS (price return, excluding dividends). Past performance does not predict future results.
Are Arrowhead Pharmaceuticals and Ionis Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.